Harvard Bioscience Inc.
HBIO
NSD
Sector: Healthcare
Industry: Medical Instruments & Supplies
2.65
USD
0.09
(3.52%)
Optionable: Yes Market Cap: 97 M 90-day average vol: 128,292
Previous close: 2.56 Open: 2.59 Bid: 2.7 Ask: 2.7
52 week range
2.27 8.23
Last updated: Tuesday 4th October 2022
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started todaySearch for a stock
Are you?
Metrics
Valuation
Price per Sales TTM ($) | 0.80 |
Price per Book TTM ($) | 1.29 |
PE Ratio (TTM) | -25.50 |
Book Value per Share ($) | 1.86 |
5 Year PE Range-703 |
Returns
7 Day Return | 10.42% | |
1 Month Return | -15.87% | |
3 Month Return | -28.18% | |
1 Year Return | -60.45% | |
3 Year Return | -13.68% | |
5 Year Return | -29.33% | |
YTD Return | -62.41% |
Risk
Financial Health
Technicals
RSI (14 Day) | 38.07 |
14 Day SMA ($) | 2.71 |
14 Day EMA ($) | 2.70 |
Money Flow Index | 54.09 |
Average True Range | 0.16 |
50 Day SMA ($) | 3.18 |
200 Day SMA ($) | 4.69 |
ADX | 9.44 |
MACD | -0.20 |
Growth
Free Cash Flow QoQ Growth | -74.28% |
Free Cash Flow YoY Growth | 0.00% |
Revenue YoY Growth | 0.00% |
EPS QoQ Growth | -135.29% |
Revenue QoQ Growth | 1.49% |
EPS YoY Growth | 0.00% |
Profitability
News
Financials
HBIO Income Statement
Annual
| Dec-12 | Dec-13 | Dec-14 | Dec-15 | Dec-16 | Dec-17 | Dec-18 | Dec-19 | Dec-20 | Dec-21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 111 M | 105 M | 109 M | 109 M | 105 M | 77 M | 121 M | 116 M | 102 M | 119 M |
| Cost of sales | 53 M | 52 M | 54 M | 54 M | 50 M | 32 M | 47 M | 42 M | 35 M | 42 M |
| Gross operating profit | 54 M | 49 M | 51 M | 50 M | 50 M | 41 M | 66 M | 66 M | 60 M | 69 M |
| Selling Gen & administrative expense | 37 M | 37 M | 35 M | 40 M | 41 M | 33 M | 46 M | 46 M | 43 M | 49 M |
| Research & development expense | 4 M | 4 M | 5 M | 6 M | 5 M | 6 M | 11 M | 11 M | 9 M | 11 M |
| Operating income | 8 M | 4 M | 7 M | -925000 | -1 M | -635000 | 984000 | 2 M | 221000 | 2 M |
| floaterest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| floaterest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other income net | -710000 | -2 M | -2 M | -2 M | -1 M | -1 M | -4 M | -2 M | -3 M | -666000 |
| Pre-tax Income (EBT) | 7 M | 435000 | 4 M | -4 M | -3 M | -3 M | -8 M | -6 M | -7 M | -140000 |
| Income taxes | 2 M | -288000 | 2 M | 15 M | 1 M | -605000 | -4 M | -815000 | 518000 | 148000 |
| Net income from total operations | 2 M | -2 M | 2 M | -19 M | -4 M | -865000 | -3 M | -5 M | -8 M | -288000 |
| Minority floaterest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total net income | 2 M | -2 M | 2 M | -19 M | -4 M | -865000 | -3 M | -5 M | -8 M | -288000 |
| Preferred dividends | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net income available for common | 4 M | 723000 | 2 M | -19 M | -4 M | -2 M | -4 M | -5 M | -8 M | -288000 |
| Depreciation | 4 M | 4 M | 4 M | 5 M | 4 M | 4 M | 8 M | 8 M | 8 M | 8 M |
| Amortization | 3 M | 3 M | 3 M | 3 M | 3 M | 2 M | 5 M | 6 M | 6 M | 6 M |
| Operating income before depreciation (EBITDA) | 12 M | 5 M | 9 M | 2 M | 2 M | 2 M | 5 M | 8 M | 5 M | 9 M |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Basic EPS total | 0.08 | -0.06 | 0.07 | -0.57 | -0.13 | -0.02 | -0.08 | -0.12 | -0.2 | -0.01 |
| Diluted EPS total | 0.08 | -0.06 | 0.07 | -0.57 | -0.13 | -0.02 | -0.08 | -0.12 | -0.2 | -0.01 |
Call: 1-877-778-8358
I am so happy you are here. My name is Ankur and I am the founder/CEO of MarketXLS. Over the past four years, I have helped more than 2500 customers to implement their own investment research strategies and monitoring systems in Excel.
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONSGet started today